As reported in WSJ and Fierce Biotech this morning another cancer drug has failed to meet its endpoint in a phase III trial. This time it is AZ's zibotentan for the treatment of prostate cancer. The drug is currently in two additional late stage trials but this result will dealy its planned filing date for approval. a few more bad results may stop it in its tracks.
AZ's drug was seen as a potential competitor to Dendreon's Provenge - which has come under some scrutiny regarding its pricing and its availability. In general, the AZ news should be good news for Dendreon. For AZ, this result complete the trifecta of disappointing news in late stage cancer trials as its Recentin (colon cancer) and Vandetanib (non-small cell lung cancer) also failed to meet key endpoints.
Posted by Bruce Lehr September 27th 2010.